Get the Stockscreener App
2.05
6.22%
0.12
Pre-market:
1.89
-0.16
-7.80%
Biovie Inc stock is traded at $2.05, with a volume of 504.99K.
It is up +6.22% in the last 24 hours and up +46.43% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.93
Open:
$1.9
24h Volume:
504.99K
Relative Volume:
0.12
Market Cap:
$17.32M
Revenue:
-
Net Income/Loss:
$-19.92M
P/E Ratio:
-0.4799
EPS:
-4.2716
Net Cash Flow:
$-20.51M
1W Performance:
+2.50%
1M Performance:
+46.43%
6M Performance:
+45.39%
1Y Performance:
+9.63%
1-Day Range:
$1.88
$2.12
1-Week Range:
$1.88
$2.20
52-Week Range:
$0.82
$3.79
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
2.05 | 16.31M | 0 | -19.92M | -20.51M | -4.2716 |
VRTX
Vertex Pharmaceuticals Inc
|
519.51 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.74 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.54 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
146.69 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
205.11 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
Biovie seeks FDA meeting to plan Phase 3 trial for Parkinson’s drug candidate - parkinsonsnewstoday.com
Jane Street Group Expands BioVie Inc (BIVI) Stake by Over 1,100% - GuruFocus
Market movers: Novartis, Qualcomm, EchoStar, BioVie... - proactiveinvestors.com
BioVie advances bezisterim Phase 3 Parkinson’s trial - grafa.com
BioVie advances Parkinson’s Phase 3 trial plans after positive Phase 2 results and FDA engagement. - Pluang
BioVie advances Parkinson’s Phase 3 development program with FDA engagement - Yahoo Finance
BioVie Announces Update to Parkinson’s Phase 3 Development Program - markets.businessinsider.com
BioVie seeks FDA feedback on a proposed Parkinson’s trial of about 175 patients. - Stock Titan
Biovie Stock Price Forecast. Should You Buy BIVI? - StockInvest.us
Jane Street reports over 5% stake in BioVie (BIVI) - stocktitan.net
Small cap wrap: Alvopetro, Royal Road Minerals, Nextech3D.ai, TNR Gold... - Proactive financial news
Market movers: PG&E, Aon, Eli Lilly, BioVie... - Proactive financial news
BioVie completes final patient visit in Phase 2 Long COVID trial, topline results due by September 2026 - Pluang
BioVie (BIVI) Completes Final Visit in ADDRESS-LC Phase 2 Trial for Long COVID Neurological Symptoms - GuruFocus
BioVie Announces Completion of Treatment Phase of - GlobeNewswire
Dow falls as US strikes Iran, rate-hike bets jump - proactiveinvestors.co.uk
BioVie completes final patient visit in Phase 2 Long COVID trial - Proactive financial news
Price to earnings forward of BioVie Inc. – BOATS:BIVIW - TradingView
Biovie CFO Joanne Kim buys $5,450 in Biovie Inc. stock By Investing.com - Investing.com Australia
Insider Stock Purchases: August 29, 2026 - Moomoo
BioVie Stock (BIVI) Opinions on Phase 2 Trial Results - Quiver Quantitative
BioVie Inc. CEO Cuong V Do buys $31,636 in company stock - Investing.com India
Biovie director Amy Chappell acquires $1,570 in BIVI common stock By Investing.com - Investing.com India
BioVie Inc (BIVI) Chief Medical Officer Joseph Palumbo Buys 4,84 - GuruFocus
Biovie CMO Joseph Palumbo buys $10,460 in common stock By Investing.com - Investing.com Canada
BioVie (NASDAQ: BIVI) CMO boosts stake with open-market share buy - Stock Titan
Biovie CFO Joanne Kim buys $5,450 in Biovie Inc. stock - Investing.com
Biovie CMO Joseph Palumbo buys $10,460 in common stock - Investing.com
Anixa Biosciences Inc. (ANIX) Peer Comparison – Compare with Others - Value Research
BioVie (BIVI) Shares: Moves 9.74% Up to $2.14 in the Latest Session; Boundary Watch - vinanet.vn
BioVie (BIVI) Results at a Glance: EPS Prints Above Forecast in the Current Update; Stock Move: The Stock Ends Up 4.84% at the CloseEarnings Sentiment Score - vinanet.vn
Number of shareholders of BioVie Inc. – NASDAQ:BIVIW - tradingview.com
New to The Street Broadcasts Today Across Bloomberg Television U.S., Latin America and MENA at 6:30 PM ET - Newswire.com
BioVie (BIVIW) Trading: Records a 1.75% Decrease to $0.28 in the Latest Session; the Supplied Trading Band Runs From $0.27 to $0.29 on the DayIndex Put Call - vinanet.vn
BIVI Jumps As BioVie Reports Strong Parkinson’s Trial Data - StocksToTrade
BioVie Inc.Warrant (Nasdaq:BIVIW) Stock Quote - FinancialContent
BIVI Stock Pops As SUNRISE-PD Parkinson’s Data Fuel Hype - timothysykes.com
BioVie (BIVI) Jumps As SUNRISE-PD Data Fuel Bullish Hopes - StocksToTrade
Which stocks are moving before the opening bell on Friday? - ChartMill
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Sahm
BioVie (BIVI) Financial Update: Profit Per Share Surpasses Its Benchmark in Latest Trading; Share Response: Shares Close 38.81% Higher on the DayWeak Earnings Momentum - vinanet.vn
MicroCaps IGC, BIVI, ORBS, RIME Sub-$1 Stocks to Watch Now - Barchart.com
BioVie (BIVI) Revenue BreakdownMain Composition - Moomoo
$BioVie (BIVI.US)$ told yall yesterday - Moomoo
BIVI Stock Draws Trader Focus After Strong Parkinson’s Data - StocksToTrade
BIVI Stock Draws Attention After Strong Parkinson’s Data - StocksToTrade
$BioVie (BIVI.US)$ Ready for lift off - Moomoo
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
New 8.4% BioVie (NASDAQ: BIVI) stake sits entirely in warrants - Stock Titan
BIVI Stock In Focus After SUNRISE-PD Trial Breakthrough - StocksToTrade
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biovie Inc Stock (BIVI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chappell Amy Suzon | Director |
Aug 28 '26 |
Buy |
2.16 |
727 |
1,570 |
727 |
| KIM JOANNE WENDY | Chief Financial Officer |
Aug 28 '26 |
Buy |
2.18 |
2,500 |
5,450 |
3,441 |
| DO CUONG V | President & CEO |
Aug 27 '26 |
Buy |
2.08 |
15,210 |
31,637 |
16,117 |
0.75%
3.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):